Kopp Family Office, LLC
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 13, 2025), Kopp Family Office, LLC reported 21 stock positions worth $157.8 million. Its top holding was Vanguard Ftse Developed ETF (VEA) at 18.6% of the portfolio, followed by Vanguard Ftse Emerging Marke (VWO, 11.1%) and Vericel (VCEL, 9.4%). Compared with Q3 2024, it sold out of 1, added to 5 and reduced 12. The biggest buy was iShares Core S&P Midcap ETF (IJH, shares +9539%) and the biggest sale an exit from Jamf (JAMF).
- Most Recent 13F
- Q2 2026
- Location
- MINNETONKA, MN
- CIK
- 0001683689
- Portfolio Value
- $157.8M (Q4 2024)
- SEC Filing
- 0001683689-25-000001 ↗ filed Feb 13, 2025
Holdings Value
Holdings 21 stocks · $157.8M
| VEA Vanguard Ftse Developed ETF | 18.57% | 613,035 | $29.3M | Reduce -0.1% |
| VWO Vanguard Ftse Emerging Marke | 11.09% | 397,415 | $17.5M | Reduce -0.1% |
| VCEL Vericel Corp. | 9.38% | 269,518 | $14.8M | Reduce -27.7% |
| NEO Neogenomics Inc. | 8.65% | 828,575 | $13.7M | Reduce -10.6% |
| FIVN FIVE9 Inc. | 8.55% | 332,245 | $13.5M | Reduce -5.6% |
| WK Workiva Inc. | 7.74% | 111,588 | $12.2M | Reduce -0.1% |
| TEAM Atlassian Corp. Ltd. Class A | 7.65% | 49,634 | $12.1M | Reduce -0.1% |
| AGG iShares Core U.S. Aggregate | 6.63% | 108,000 | $10.5M | Add +11.3% |
| IWM iShares Russell 2000 ETF | 6.19% | 33,955 | $9.8M | No change |
| INSP Inspire Medical Systems Inc. | 4.82% | 41,041 | $7.6M | Reduce -0.1% |
| NTNX Nutanix Inc. Class A | 3.78% | 97,604 | $6.0M | Reduce -0.1% |
| VRDN Viridian Therapeutics Inc. | 2.50% | 205,407 | $3.9M | Reduce -0.2% |
| IJH iShares Core S&P Midcap ETF | 2.15% | 54,463 | $3.4M | Add +9539.5% |
| RSP Invesco S&P 500 Equal Weight | 2.00% | 18,000 | $3.2M | No change |
| ISTB iShares Core 1-5 Year Usd Bo | 0.07% | 2,173 | $104K | Add +7.8% |
| IEFA iShares Core MSCI Eafe ETF | 0.06% | 1,400 | $98K | No change |
| IVV iShares Core S&P 500 ETF | 0.06% | 159 | $94K | Reduce -19.3% |
| IEMG iShares Core MSCI Emerging | 0.04% | 1,150 | $60K | No change |
| IAGG iShares Intl Aggregate Bond | 0.03% | 839 | $42K | Add +4.1% |
| IMTB iShares Core 5-10 Year Usd | 0.02% | 911 | $39K | Add +9.2% |
| IJR iShares Core S&P Small-Cap E | 0.01% | 141 | $16K | Reduce -14.0% |
Portfolio Sells Q3 2024 → Q4 2024
| JAMF Jamf Holding Corp. | Sold out | 0.00% | −4.45 |
| VEA Vanguard Ftse Developed ETF | Reduce -0.1% | 18.57% | −2.06 |
| VWO Vanguard Ftse Emerging Marke | Reduce -0.1% | 11.09% | −1.03 |
| INSP Inspire Medical Systems Inc. | Reduce -0.1% | 4.82% | −0.70 |
| VCEL Vericel Corp. | Reduce -27.7% | 9.38% | −0.66 |
| VRDN Viridian Therapeutics Inc. | Reduce -0.2% | 2.50% | −0.49 |
| NEO Neogenomics Inc. | Reduce -10.6% | 8.65% | −0.05 |
| IVV iShares Core S&P 500 ETF | Reduce -19.3% | 0.06% | −0.01 |
| IJR iShares Core S&P Small-Cap E | Reduce -14.0% | 0.01% | −0.00 |
| NTNX Nutanix Inc. Class A | Reduce -0.1% | 3.78% | +0.10 |
| FIVN FIVE9 Inc. | Reduce -5.6% | 8.55% | +2.11 |
| WK Workiva Inc. | Reduce -0.1% | 7.74% | +2.11 |
| TEAM Atlassian Corp. Ltd. Class A | Reduce -0.1% | 7.65% | +2.63 |
Portfolio Buys Q3 2024 → Q4 2024
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 29 | $163.2M | AGG, VEA, RSP, SPY, VWO |
| Q1 2026 | 21 | $145.3M | VEA, AGG, RSP, SPY, VWO |
| Q4 2025 | 21 | $156.7M | VEA, RSP, IJH, VWO, AGG |
| Q3 2025 | 26 | $153.6M | VEA, VWO, RSP, IJH, AGG |
| Q2 2025 | 27 | $154.5M | VEA, VWO, RSP, AGG, IJH |
| Q1 2025 | 28 | $144.7M | VEA, VWO, AGG, FIVN, WK |
| Q4 2024 | 21 | $157.8M | VEA, VWO, VCEL, NEO, FIVN |
| Q3 2024 | 22 | $157.0M | VEA, VWO, VCEL, NEO, FIVN |
| Q2 2024 | 21 | $161.2M | VEA, IWM, VCEL, VWO, FIVN |
| Q1 2024 | 21 | $175.1M | VEA, IWM, VCEL, VWO, FIVN |